GRO1 inhibitors are a distinct class of chemical compounds that function by targeting and inhibiting the activity of the Growth-regulated oncogene 1 (GRO1) protein. GRO1, also known as CXCL1, is a chemokine involved in various cellular processes including cell proliferation, migration, and angiogenesis. The inhibition of GRO1 can result in the modulation of signaling pathways that regulate these fundamental cellular activities. GRO1 inhibitors typically achieve this by binding to the GRO1 protein or its receptor, CXCR2, thereby blocking the interaction and subsequent downstream signaling cascades. This blockade can alter the expression of various genes and proteins involved in the regulation of the cell cycle, apoptosis, and other cellular mechanisms.
In the realm of biochemical research, GRO1 inhibitors are instrumental in elucidating the underlying mechanisms of GRO1-related cellular processes. They serve as crucial tools in studying the regulatory networks influenced by GRO1 and its associated signaling pathways. By modulating GRO1 activity, researchers can gain insights into the protein's role in cellular dynamics and its broader implications in tissue homeostasis and pathology. Moreover, GRO1 inhibitors are often employed in various experimental models to investigate the effects of GRO1 inhibition on cell behavior, including changes in gene expression profiles, alterations in cellular morphology, and impacts on cell-cell communication. Through such studies, GRO1 inhibitors contribute significantly to our understanding of the molecular basis of cellular functions and the intricate web of signaling pathways governing these processes.
| 제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
|---|---|---|---|---|---|---|
Reparixin | 266359-83-5 | sc-507446 | 5 mg | $76.00 | ||
레파릭신은 CXCL의 주요 수용체인 CXCR1 수용체를 표적으로 하는 저분자 길항제로, CXCL1에 의한 염증 및 호중구 모집에 억제 효과를 나타냅니다. | ||||||
AZD 5069 | 878385-84-3 | sc-507447 | 5 mg | $230.00 | ||
AZD5069는 CXCR의 선택적 저분자 길항제로 CXCL1 매개 호중구 이동에 대한 억제 효과를 보였으며 염증성 폐 질환에 대한 연구에서 연구되었습니다. | ||||||
SB 225002 | 182498-32-4 | sc-202803 sc-202803A | 1 mg 5 mg | $35.00 $100.00 | 2 | |
SB225002는 CXCR을 표적으로 하는 저분자 길항제로, CXCL1에 의한 호중구 활성화 및 이동에 대한 억제 효과를 입증했습니다. | ||||||